reversan

Reversan is a small-molecule pyrazolo[1,5-a]pyrimidine derivative that acts as an inhibitor of multidrug resistance-associated protein 1 (MRP1 / ABCC1) and P-glycoprotein (P-gp / ABCB1). Developed by Cleveland BioLabs in collaboration with the Children's Cancer Institute Australia and Roswell Park Comprehensive Cancer Center, Reversan was identified through a cell-based screen designed to find agents that reverse transporter-mediated multidrug resistance (MDR) in cancer. It has been shown to significantly increase the intracellular accumulation and efficacy of chemotherapeutic agents such as doxorubicin, vincristine, and etoposide in preclinical models of neuroblastoma and glioblastoma multiforme. Unlike earlier generation efflux pump inhibitors, Reversan exhibits low intrinsic toxicity and does not interfere with CYP3A4, offering a more favorable therapeutic index.

Other names

N-(3-morpholinopropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamideN-[3-(4-morpholinyl)propyl]-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide